Zai gains Hong Kong approval of PARP inhibitor Zejula

Zai Lab Ltd. (NASDAQ:ZLAB) is preparing for its first product launch after Hong Kong's Department of Health approved its PARP inhibitor Zejula niraparib to treat platinum-sensitive, relapsed ovarian cancer in adults who are

Read the full 333 word article

User Sign In